BlueWind Medical Raises $47.8M in Equity and Debt

The company plans to use the funding to accelerate the commercialization of its Revi® System, expand its sales team, and expand market access efforts to make the treatment available to more patients and healthcare providers.

The financing follows several important clinical milestones achieved over the past year, including three-year results from the pivotal OASIS study, which showed that the Revi® System delivered long-term effectiveness, strong safety results, and a 95% patient satisfaction rate after 36 months.

"This financing is an important milestone for BlueWind and a strong validation of the progress we are making as a leader in Implantable Tibial Neuromodulation for urgency urinary incontinence," said Stephen Armstrong, Chief Financial Officer of BlueWind Medical. "The capital allows us to scale our commercial organization, expand market access, and ensure that more patients and providers can benefit from a clinically proven, patient-centric therapy. We are grateful for the continued confidence of our investors as we execute on the next phase of our growth."

Read More:Graphon AI Raises $8.3M in Seed Funding

"Urgency urinary incontinence affects millions of people, creating a significant need for effective, durable treatment options that fit seamlessly into patients’ lives," said Kerry Nelson, Chief Executive Officer of BlueWind Medical. "This financing reflects deep conviction in our team, our technology and the opportunity ahead to establish Revi as the new standard of care."

About BlueWind Medical Ltd.

BlueWind Medical is developing neuromodulation technologies to improve patient care and quality of life, with an initial focus on treating urgency urinary incontinence (UUI). Its Revi® System is the first FDA-cleared implantable tibial neuromodulation device activated by an external, battery-powered wearable device for the treatment of UUI patients.

Read More:Rango Receives $25M Debt Facility From White Oak Commercial Finance